Tivozanib Promising for Metastatic Renal Cell Carcinoma
Updated clinical trial results reveal Tivozanib superior to Nexavar and headed to the FDA for US approval.12/13/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology